<DOC>
	<DOCNO>NCT01802892</DOCNO>
	<brief_summary>The present study aim evaluate impact 5 day oral administration ronacaleret 100 miligram ( mg ) 400 mg change circulate CD34+ cell , ronacaleret follow administration single dose plerixafor healthy human volunteer . This single centre adaptive design study carry 2 part . The part A evaluate change peripheral circulating CD34+ cell response two different 5 day regimen ronacaleret ( 100 mg 400 mg daily ) , give conjunction single dose plerixafor ( 0.24 mg/kilogram [ kg ] ) sub-cutaneously ( SC ) even final day dose approximately 12 hour collection CD34+ cell day 6 . Subjects ( 5 ) assign either one ronacaleret arm , open fashion . Comparisons make change baseline end treatment peripheral CD34+ cell count . Part A conducted two cohort 5 subject enrol 2 treatment arm make first cohort . Cohort 2 involve 5 subject enrol treatment arm . The structure part B finalize follow review data generate part A . The total study duration Part A subject include screening , treatment follow-up period approximately 7 week .</brief_summary>
	<brief_title>Study Healthy Volunteers , Evaluate Safety , Efficacy Dose Responses SB-751689 ( Ronacaleret )</brief_title>
	<detailed_description />
	<mesh_term>JM 3100</mesh_term>
	<criteria>A male female 18 65 year age ( inclusive ) . Healthy determine physician , base medical evaluation estimate Glomerular Filtration Rate ( GFR ) &gt; =60 mL/min /1.73 m^2 use four variable Modification Diet Renal Disease ( MDRD ) equation . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Female nonchild bear potential , female subject male subject female partner childbearing potential willing use protocolspecified method contraception prevent pregnancy study . Body weight 55 kg body mass index ( BMI ) 20.0 35.0 kg/m^2 ( inclusive ) . Capable give write informed consent . A positive prestudy drug/alcohol screen . A positive test HIV , B surface antigen positive Hepatitis C antibody result within 3 month screen . History therapy osteoporosis Subject treatment condition relate thyroid/parathyroid gland opinion investigator may influence subject production PTH Subjects contraindication know allergy receive plerixafor Current chronic history liver disease , know hepatic biliary abnormality ( exception asymptomatic gallstone ) . Subjects take calcium and/or vitamin D supplement , within 2 week study initiation Subjects take concomitant medication Specific laboratory abnormality screen like Serum calcium ( total albuminadjusted ) outside central laboratory reference range , PTH outside normal range , Creatine phosphokinase ( CPK ) outside normal range Subjects abnormal Vitamin D ( Vitamin D , 25Hydroxy ) level may enrol repeat lab result , obtain within 14 day initial screening assessment , within normal range History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . Lactating pregnant female determine positive serum human chorionic gonadotropin ( hCG ) test screen prior dosing . The subject participate clinical trial within 30 day 5 halflives IP prior first dose day current study . Unable refrain consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose . Where participation study would result donation blood blood product excess 500 mL within 56 day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ronacaleret</keyword>
	<keyword>parathyroid hormone ( PTH )</keyword>
	<keyword>CD34+cells</keyword>
	<keyword>calcium sense receptor antagonist</keyword>
	<keyword>hematopoietic stem cell</keyword>
	<keyword>stem cell mobilization</keyword>
	<keyword>plerixafor</keyword>
	<keyword>healthy human volunteer , phase Ib</keyword>
</DOC>